MedTrace Logo

Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment

NCT06666114 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 232

Last updated 2024-10-30

No results posted yet for this study

Summary

This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites. At least 12 months of patient data was verified, comprising at least 6 months (pre-period) and 6 months (post-period) after secukinumab initiation (index date). All data extracted from patient charts was entered into an electronic case report form (eCRF), specifically designed to capture all variables needed for the study data analysis.

Conditions

  • Psoriasis (PsO)
  • Psoriatic Arthritis (PsA)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-03
Primary Completion
2023-10-10
Completion
2023-10-10

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06666114 on ClinicalTrials.gov